Clinical Trials
20 trialsNCT06152575 2026-05-22
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
Pfizer
Phase 3 Recruiting
NCT04751877 2026-02-10
Multicenter Open Label Phase 3 Study of Isatuximab Plus Lenalidomide and Dexamethasone With/Without Bortezomib in the Treatment of Newly Diagnosed Non Frail Transplant Ineligible Multiple Myeloma Elderly Patients (≥ 65; < 80 Years).
Poitiers University Hospital
Phase 3 Active not recruiting
NCT01208662 2026-01-22
DFCI 10-106
Dana-Farber Cancer Institute
Phase 3 Active not recruiting
NCT01208766 2026-01-06
HO95
Stichting Hemato-Oncologie voor Volwassenen Nederland
Phase 3 Completed
NCT00002878 2023-06-15
Combination Chemotherapy With or Without PSC 833 in Treating Patients With Relapsed or Refractory Multiple Myeloma
Eastern Cooperative Oncology Group
Phase 3 Completed
NCT00075829 2021-11-01
BMT CTN 0102
National Heart, Lung, and Blood Institute (NHLBI)
Phase 3 Completed
NCT00002678 2020-04-02
Combination Chemotherapy in Treating Patients With Multiple Myeloma
Canadian Cancer Trials Group
Phase 3 Completed
NCT01023308 2020-03-17
PANORAMA-1
Novartis
Phase 3 Completed
NCT01311687 2018-10-24
NIMBUS
Celgene
Phase 3 Completed
NCT01554852 2018-06-11
Myeloma XI
University of Leeds
Phase 3 Unknown
NCT00477971 2016-05-17
Low-Dose Melphalan and Dexamethasone Compared With High-Dose Melphalan Followed By Autologous Stem Cell Transplant in Treating Patients With Primary Systemic Amyloidosis
Mayo Clinic
Phase 3 Completed
NCT00111748 2015-10-06
UARK 2005-01 Study of Velcade, Thalidomide, and Dexamethasone (VTD) With or Without Adriamycin® in Relapsed/Refractory Patients
University of Arkansas
Phase 3 Completed
NCT00064038 2015-03-25
S0232 Dexamethasone With or Without Lenalidomide in Treating Patients With Previously Untreated Stage I, Stage II, or Stage III Multiple Myeloma
SWOG Cancer Research Network
Phase 3 Completed
NCT00033332 2014-04-04
Dexamethasone With or Without Thalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma
National Cancer Institute (NCI)
Phase 3 Completed
NCT00017602 2014-01-06
Dexamethasone With or Without Oblimersen in Treating Patients With Relapsed or Refractory Multiple Myeloma
National Cancer Institute (NCI)
Phase 3 Completed
NCT00003603 2013-09-20
Chemotherapy Plus Steroid Therapy in Treating Patients With Multiple Myeloma
National Cancer Institute (NCI)
Phase 3 Unknown
NCT00028886 2013-09-17
Combination Chemotherapy With or Without Thalidomide in Treating Patients With Multiple Myeloma
National Cancer Institute (NCI)
Phase 3 Unknown
NCT00416897 2013-08-26
Dexamethasone and Chemotherapy With or Without Plasma Exchange in Patients With Newly Diagnosed Multiple Myeloma and Acute Kidney Failure
National Cancer Institute (NCI)
Phase 3 Completed
NCT00006232 2013-05-15
Combination Chemotherapy in Treating Patients With Stage II or Stage III Multiple Myeloma
National Cancer Institute (NCI)
Phase 3 Completed
NCT00344422 2011-06-10
Vincristine, DOXIL (Doxorubicin HCl Liposome Injection) and Dexamethasone vs. Vincristine, Doxorubicin, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Phase 3 Completed